V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study.

@article{Moreland1996VB1,
  title={V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study.},
  author={Larry Moreland and Louis W. Heck and William J. Koopman and P A Saway and Thomas C Adamson and Z Fronek and R D O'connor and Elizabeth E Morgan and Jocelyn P Diveley and Steven P. Richieri and Dennis J. Carlo and Sacha Brostoff},
  journal={The Journal of rheumatology},
  year={1996},
  volume={23 8},
  pages={1353-62}
}
OBJECTIVE To determine whether modulation of activated T cells occurs in patients with rheumatoid arthritis (RA) after immunization with T cell receptor (TCR) V beta 17 peptides, a phase I trial was initiated to investigate the safety and feasibility of TCR peptide immunization as a therapeutic approach in RA. METHODS 15 patients with moderate to severe RA were given an intramuscular injection of one of 4 doses (10, 30, 100, and 300 micrograms) of the V beta 17 peptide vaccination, followed… CONTINUE READING

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…